McClure R Scott, McGurk Siobhan, Cevasco Marisa, Maloney Ann, Gosev Igor, Wiegerinck Esther M, Salvio Genina, Tokmaji George, Borstlap Wernard, Nauta Foeke, Cohn Lawrence H
Division of Cardiac Surgery, Harvard Medical School, Brigham and Women's Hospital, Boston, Mass; Division of Cardiac Surgery, Queen's University, Kingston General Hospital, Kingston, Ontario, Canada.
Division of Cardiac Surgery, Harvard Medical School, Brigham and Women's Hospital, Boston, Mass.
J Thorac Cardiovasc Surg. 2014 Nov;148(5):1931-9. doi: 10.1016/j.jtcvs.2013.12.042. Epub 2014 Jan 15.
Our study compares late mortality and valve-related morbidities between nonelderly patients (aged <65 years) undergoing stented bioprosthetic or mechanical valve replacement in the aortic position.
We identified 1701 consecutive patients aged <65 years who underwent aortic valve replacement between 1992 and 2011. A stented bioprosthetic valve was used in 769 patients (45%) and a mechanical valve was used in 932 patients (55%). A stepwise logistic regression propensity score identified a subset of 361 evenly matched patient-pairs. Late outcomes of death, reoperation, major bleeding, and stroke were assessed.
Follow-up was 99% complete. The mean age in the matched cohort was 53.9 years (bioprosthetic valve) and 53.2 years (mechanical valve) (P=.30). Fifteen additional measurable variables were statistically similar for the matched cohort. Thirty-day mortality was 1.9% (bioprosthetic valve) and 1.4% (mechanical valve) (P=.77). Survival at 5, 10, 15, and 18 years was 89%, 78%, 65%, and 60% for patients with bioprosthetic valves versus 88%, 79%, 75%, and 51% for patients with mechanical valves (P=.75). At 18 years, freedom from reoperation was 95% for patients with mechanical valves and 55% for patients with bioprosthetic valves (P=.002), whereas freedom from a major bleeding event favored patients with bioprosthetic valves (98%) versus mechanical valves (78%; P=.002). There was no difference in stroke between the 2 matched groups.
In patients aged <65 years, despite an increase in the rate of reoperation with stented bioprosthetic valves and an increase in major bleeding events with mechanical valves, there is no significant difference in mortality at late follow-up.
我们的研究比较了主动脉位置接受带支架生物瓣膜或机械瓣膜置换的非老年患者(年龄<65岁)的晚期死亡率和瓣膜相关并发症。
我们确定了1992年至2011年间连续1701例年龄<65岁接受主动脉瓣置换的患者。769例患者(45%)使用带支架生物瓣膜,932例患者(55%)使用机械瓣膜。通过逐步逻辑回归倾向评分确定了361对匹配良好的患者亚组。评估了死亡、再次手术、大出血和中风的晚期结局。
随访完成率为99%。匹配队列中生物瓣膜组的平均年龄为53.9岁,机械瓣膜组为53.2岁(P = 0.30)。匹配队列的另外15个可测量变量在统计学上相似。生物瓣膜组30天死亡率为1.9%,机械瓣膜组为1.4%(P = 0.77)。生物瓣膜置换患者在5年、10年、15年和18年的生存率分别为89%、78%、65%和60%,而机械瓣膜置换患者分别为88%、79%、75%和51%(P = 0.75)。18年时,机械瓣膜置换患者再次手术率为95%,生物瓣膜置换患者为55%(P = 0.002),而生物瓣膜置换患者大出血事件发生率低于机械瓣膜置换患者(98%对78%;P = 0.002)。两组匹配组之间中风发生率无差异。
在年龄<65岁的患者中,尽管带支架生物瓣膜的再次手术率增加,机械瓣膜的大出血事件增加,但晚期随访死亡率无显著差异。